ArticleActa diabetologica2026
A multicenter prospective evaluation of the benefits of Dexcom ONE + in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study.
Ana Chico et al.PubMed ↗Publisher ↗
No numbers read from the abstract.